| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Vaccines | Infectious Diseases | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Vaccines | Infectious Diseases | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Vaccines | Infectious Diseases |
Recent Updates
Recently added Catalysts
Evaxion A/S$3.17
+0.12 (+3.75%)
D 24Pipeline Score Richly Valued Biotech · Clinical
Market Cap
34.03 M
EPS
-1.38
P/E Ratio
-
Value Trade
71.12 K
-1.45 %
Week
-9.93 %
1 Month
17.24 %
3 Month
-25 %
6 Month
-98.88 %
5 Year
-99.18 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
10.09 K
52 Week Range
1.95 - 12.15
% held by Insiders
19.22 %
% held by Institutions
5.12 %
Enterprise Value
15.59 M
Total Shares
8.34 M
Short %
0.45 %
Float Shares
6.74 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Evaxion A/S
159Total events
9Upcoming
31Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 9
Jul 12, 2026
T3Poster Presentation
Poster presentation of new preclinical data for EVX-V1 at IHW 2026
Event history 150
Jun 13, 2026
◆Poster PresentationEVX-04Presentation
Poster presentation at EHA 2026 Congress
acute myeloid leukemiasource ↗
Jun 12, 2026
▲Oral PresentationPresentation
Evaxion receives Prix Galien UK Award for Best digital health solution for AI-Immunology platform
Jun 11, 2026
▲Preclinical PoCEVX-04Preclinical
New preclinical data demonstrating EVX-04 expression, secretion, immune recognition, and targeted cell-killing
acute myeloid leukemiasource ↗
May 7, 2026
May 7, 2026
▲Management ChangeCorporate
Promotion of Birgitte Rønø to Chief Scientific and Chief Operating Officer
Apr 22, 2026
◆Poster PresentationPresentation
Poster presentation at AACR Annual Meeting on ERV-derived neoantigens for glioblastoma vaccine
glioblastomasource ↗
Apr 22, 2026
◆Poster PresentationEVX-01Presentation
Poster presentation of EVX-01 data at AACR 2026
advanced melanomasource ↗
Apr 7, 2026
▲Last Patient Last VisitEVX-01Trial
Last patient visit in one-year extension of phase 2 trial
advanced melanomasource ↗
Apr 2, 2026
◆Oral PresentationEVX-V1Presentation
Presentation of AI-powered target discovery for novel CMV vaccine (EVX-V1) at World Vaccine Congress
Cytomegalovirus (CMV)source ↗
Q2 2026
◆IND SubmissionEVX-04IND
Planned clinical trial application submission for EVX-04
acute myeloid leukemiasource ↗
Drug Pipeline Intelligence
D24
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 23%
Micro Cap (rank 702 of 911)
Percentile RankEvaxion A/S faces pipeline headwinds (24/100), with $56M risk-adjusted pipeline value, led by EVX-01 in Melanoma Stage IV (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EVX-01 Small molecule | Melanoma Stage IV | Phase 2 | NCT05309421 | 10% | $56M | ACTIVE NOT_RECRUITING | 17 | STALLED | D (20) | Mar 30, 2026 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EVX-01 | advanced melanoma | Phase 2 | 2026-04-17 | In the Phase 2 trial of the personalized cancer vaccine EVX-01 for advanced melanoma, 86% of vaccine targets triggered a tumor-specific immune response, and the trial reported a 75% Objective Response Rate after two years of treatment. Read More | Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial Read More | |
EVX-01 | advanced melanoma | Phase 2 | 2026-04-17 | In the Phase 2 trial of the personalized cancer vaccine EVX-01 for advanced melanoma, 86% of vaccine targets triggered a tumor-specific immune response, and the trial reported a 75% Objective Response Rate after two years of treatment. Read More | Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial Read More | |
EVX-01 | advanced melanoma | Phase 2 | 2026-04-17 | In the Phase 2 trial of the personalized cancer vaccine EVX-01 for advanced melanoma, 86% of vaccine targets triggered a tumor-specific immune response, and the trial reported a 75% Objective Response Rate after two years of treatment. Read More | Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EVAX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EVAX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EVAXEvaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Evaxion A/S will present new preclinical data for its cytomegalovirus vaccine candidate, EVX-V1, at the International Herpesvirus Workshop in Montreal. The data will aid in the final selection of antigens for the vaccine, which combines novel AI-discovered and optimized components. This innovative approach aims to enhance the vaccine's protective potential against CMV.
Read more →EVAXEvaxion receives Prix Galien UK Award for Best digital health solution
Evaxion A/S has been awarded the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology™ platform. This recognition highlights the platform's capabilities in developing novel vaccines for cancer and infectious diseases. The award was presented to CEO Helen Tayton-Martin at a ceremony in London, marking a significant achievement for the company.
Read more →EVAXEvaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Evaxion A/S has announced promising preclinical data for its therapeutic vaccine EVX-04, targeting acute myeloid leukemia (AML). The vaccine is shown to be effectively expressed and secreted in human cells, driving specific immune responses that mediate targeted cell-killing. This data will be presented at the EHA 2026 Congress, highlighting its potential as a novel treatment option for AML patients.
Read more →EVAXEvaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
Evaxion A/S will present new preclinical data for EVX-04, a therapeutic vaccine for acute myeloid leukemia (AML), at the EHA 2026 Congress in Stockholm. The data will focus on the functional characterization of EVX-04, which targets specific tumor antigens. The company plans to submit a clinical trial application later in 2026.
Read more →EVAX▼ -7.7%on this newsshared move
Evaxion announces business update and first quarter 2026 financial results
Evaxion A/S reported a positive business update alongside its Q1 2026 financial results, highlighting significant advancements in its AI-Immunology™ platform. The company achieved an 86% vaccine target recognition rate for its personalized cancer vaccine, EVX-01, and successfully extended its phase 2 trial. Additionally, Evaxion is developing new polio vaccine concepts in collaboration with The Gates Foundation. Despite a net loss increase, the company maintains a cash runway into 2027.
Read more →EVAXEvaxion to announce business update and first quarter 2026 financial results on May 7, 2026
Evaxion A/S will announce a business update and its first quarter 2026 financial results on May 7, 2026. The company, known for its AI-Immunology™ platform, will host a conference call and webcast to present these updates. The event aims to engage stakeholders and provide insights into Evaxion's ongoing projects.
Read more →EVAXEvaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
Evaxion A/S has promoted Birgitte Rønø to the dual role of Chief Scientific Officer and Chief Operating Officer. This change aims to enhance the company's strategy execution and external visibility of its AI-Immunology™ platform. Rønø's extensive contributions to the company were acknowledged in this decision, which is expected to strengthen Evaxion's capabilities in vaccine development.
Read more →EVAX▲ +7.5%on this news
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Evaxion A/S has reported promising phase 2 trial results for its personalized cancer vaccine EVX-01, demonstrating an 86% success rate in triggering tumor-specific immune responses. The data, which will be presented at the AACR Annual Meeting, highlights the effectiveness of Evaxion's AI-Immunology™ platform in identifying relevant vaccine targets. The trial also showed durable immune responses and a strong correlation between AI predictions and immune response magnitude.
Read more →EVAX▲ +7.5%on this news
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
Evaxion A/S has announced new data showcasing its AI-Immunology™ platform's capability to develop vaccines for glioblastoma. The platform identifies endogenous retrovirus-derived antigens, which could significantly improve vaccine efficacy for this challenging cancer. The findings will be presented at the upcoming AACR Annual Meeting, highlighting the potential of AI in cancer treatment.
Read more →EVAXEvaxion concludes Annual General Meeting
Evaxion A/S held its Annual General Meeting on April 16, 2026, where the 2025 Annual Report was approved, and several board members were re-elected. The meeting highlighted the company's commitment to developing novel vaccines through its AI-Immunology™ platform. Contact information for investor relations was also provided.
Read more →EVAXEvaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
Evaxion A/S has completed a one-year extension of its phase 2 trial for the personalized cancer vaccine EVX-01. The trial yielded promising results, including a 75% Objective Response Rate and sustained responses in patients. The three-year clinical efficacy data is expected to be presented in the second half of 2026, further enhancing the data package for EVX-01.
Read more →EVAX▲ +7.1%on this news
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
Evaxion A/S has developed innovative polio vaccine design concepts using its AI-Immunology™ platform, in collaboration with the Gates Foundation. These concepts aim to improve upon existing vaccines and will be presented at the World Vaccine Congress. Additionally, Evaxion will showcase data from its EVX-V1 program targeting cytomegalovirus.
Read more →EVAX▲ +5.8%on this news
Notice to convene Evaxion’s Annual General Meeting
Evaxion A/S has announced the convening of its Annual General Meeting scheduled for April 16, 2026. The meeting will take place at the company's offices in Hørsholm, Denmark. The agenda and proposals are available on Evaxion's website, highlighting the company's ongoing commitment to developing novel vaccines through its AI-Immunology platform.
Read more →EVAXEvaxion to present new data at AACR Annual Meeting
Evaxion A/S will present new data on its personalized cancer vaccine EVX-01 at the AACR Annual Meeting in April 2026. The data includes biomarker and immunogenicity results from a phase 2 trial evaluating EVX-01 in combination with KEYTRUDA® for advanced melanoma. Additionally, the company will showcase how AI-Immunology™ can identify neoantigens for glioblastoma vaccines.
Read more →EVAX▲ +9.3%on this news
Evaxion announces business update and full year 2025 financial results
Evaxion A/S reported significant advancements in 2025, including the licensing of their EVX-B3 vaccine candidate to MSD and promising results from their EVX-01 personalized cancer vaccine. The company has bolstered its financial position with over $30 million raised, allowing operations to continue into 2027. Future plans include expanding their AI-Immunology™ platform and progressing their R&D pipeline.
Read more →EVAX▲ +9.3%on this newsshared move
Evaxion plans to file 2025 annual report later today
Evaxion A/S has announced a slight delay in filing its 2025 annual report due to unforeseen technical issues with external vendors. The report is finalized and will be published as soon as possible. Consequently, a scheduled conference call has been moved to March 6, 2026, to accommodate this delay.
Read more →EVAXEvaxion to announce business update and full year 2025 financial results on March 5, 2026
Evaxion A/S will announce a business update and its full year 2025 financial results on March 5, 2026. The company will host a conference call and webcast for stakeholders to present the update and take questions. This event highlights Evaxion's commitment to transparency and innovation in vaccine development.
Read more →EVAXEvaxion expands AI-Immunology™ platform into autoimmune diseases
Evaxion A/S is expanding its AI-Immunology™ platform to include treatments for autoimmune diseases, alongside its existing focus on cancers and infectious diseases. This strategic move aims to leverage the platform's scalability and address significant unmet medical needs in autoimmune conditions. The development is expected to enhance Evaxion's pipeline and partnership potential without impacting its financial runway.
Read more →EVAX▲ +9.1%on this news
Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
Evaxion A/S announced that MSD will not exercise its option for the Gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights. Despite this setback, Evaxion remains optimistic about the vaccine's potential and plans to seek another licensing partner. The company continues to develop its AI-Immunology™ platform, which has shown promise in preclinical studies.
Read more →EVAX▲ +19.6%on this news
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
Evaxion A/S presented new data on its cancer vaccine candidate EVX-04 at the ASH Annual Meeting. The data shows that EVX-04 effectively triggers strong T-cell responses and prevents tumor growth in preclinical models. The vaccine targets specific ERV tumor antigens, offering broad coverage and the potential to improve treatment options for acute myeloid leukemia (AML) patients.
Read more →EVAX▲ +9.4%on this news
Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1
Evaxion A/S has reported promising data from its cytomegalovirus (CMV) vaccine program, EVX-V1, showcasing protective effects of newly identified antigens. The AI-Immunology™ platform has unveiled novel targets that could significantly advance CMV vaccine development. The company is progressing with preclinical studies and seeking partnerships to expedite the program's development.
Read more →EVAXEvaxion announce 2026 financial calendar
Evaxion A/S has announced its financial calendar for 2026, detailing key dates for business updates and financial results. The schedule includes updates on March 5, April 16, May 7, August 20, and November 19. The company emphasizes its commitment to developing AI-Immunology™ powered vaccines for cancer and infectious diseases.
Read more →EVAXEvaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
Evaxion A/S presented new immune response data for its personalized cancer vaccine, EVX-01, at the SITC 2025 Annual Meeting. The phase 2 trial data indicates that EVX-01, in combination with KEYTRUDA, induces a clinically relevant immune response in patients with advanced melanoma. The findings highlight the potential of AI-designed vaccines in cancer treatment.
Read more →EVAX▲ +10.6%on this newsshared move
Evaxion announces business update and third quarter 2025 financial results
Evaxion A/S has reported significant advancements in its R&D pipeline, particularly with the personalized cancer vaccine EVX-01, which demonstrated a 75% objective response rate in a phase 2 trial. The company also successfully out-licensed EVX-B3, enhancing its financial position with a $7.5 million option exercise fee. Overall, Evaxion's financial results show a net income of $4.6 million for Q3 2025, a notable improvement from the previous year.
Read more →EVAXEvaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
Evaxion A/S has announced the expansion of its research and development pipeline with the introduction of EVX-04, an AI-designed precision cancer vaccine candidate targeting acute myeloid leukemia (AML). This innovative vaccine leverages proprietary AI-Immunology™ technology to identify and utilize unique tumor antigens, aiming to provide effective treatment options for a broader patient population. Preclinical data indicates strong T-cell responses, with further details to be presented at the upcoming ASH Annual Meeting.
Read more →EVAXCorrection: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
Evaxion A/S will announce its third quarter 2025 financial results and provide a business update on November 6, 2025. The event will include a conference call and webcast, allowing public participation. The company focuses on AI-powered vaccine development, showcasing its innovative approach in the biopharma sector.
Read more →EVAXEvaxion raises $7.2 million, extending cash runway to second half of 2027
Evaxion A/S has successfully raised $7.2 million, extending its financial runway into the second half of 2027. This funding comes from an at-the-market offering and the exercise of investor warrants, bolstered by a $7.5 million licensing deal with MSD for its vaccine candidate. Despite this positive development, the company still faces a debt of $9.2 million and anticipates significant operational expenses in 2025.
Read more →EVAXEvaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
Evaxion A/S has appointed Dr. Helen Tayton-Martin as its new CEO, effective November 24, 2025. Dr. Tayton-Martin, who holds a Ph.D. in molecular immunology, previously co-founded Adaptimmune and has extensive experience in the biotech sector. The transition comes as Evaxion aims to leverage its AI-Immunology platform for further advancements in vaccine development.
Read more →EVAX▼ -29.3%on this news· ran to -43% by day 3
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
Evaxion A/S announced promising two-year results from its phase 2 trial of the personalized cancer vaccine EVX-01, showing a 75% Objective Response Rate in advanced melanoma patients. Notably, 92% of participants continued to respond after 24 months, with no relapses reported. The vaccine, developed using AI-Immunology™, targets unique tumor proteins and has shown high immunogenicity. The results highlight the potential of EVX-01 as a new treatment option in oncology.
Read more →EVAX▲ +6.1%on this news· ran to +63% by day 3
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
Evaxion A/S will present data from its phase 2 trial of the personalized cancer vaccine EVX-01 at the ESMO Congress 2025. The presentation will include two-year clinical efficacy, immunogenicity, and safety data. The trial, which combines EVX-01 with KEYTRUDA, has shown promising results, including a 69% overall response rate in advanced melanoma patients.
Read more →EVAX▼ -5.4%on this news· ran to +18% by day 1
OF EXTRAORDINARY GENERAL MEETING
Evaxion Biotech A/S announces an extraordinary general meeting scheduled for January 2025, where the board will propose significant changes to the company's share capital. This includes reducing the nominal share capital from DKK 58,660,556 to DKK 14,665,139 due to losses. Additionally, the nominal value of each share is set to change from DKK 1 to DKK 0.25. The company aims to authorize adjustments to issued warrants to reflect these changes.
Read more →EVAXMarch 2024 NOTICE OF ANNUAL GENERAL MEETING EVAXION BIOTECH A/S 16 APRIL 2024 AT 15:00 (CEST) The board of directors hereby convenes the annual general meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76
Evaxion Biotech A/S has convened its annual general meeting for April 16, 2024, where shareholders will review the company's activities and financial performance for 2023. The board of directors recommends the approval of the audited annual report and proposes the re-election of existing board members while also introducing new candidates. Additionally, the board seeks authorization to issue new warrants and increase the company's share capital, signaling potential for future growth and investment.
Read more →EVAXEvaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
Evaxion Biotech A/S has officially regained compliance with Nasdaq's minimum bid price requirement, as confirmed by the Notification Letter received on February 5, 2024. The company's American Depositary Shares maintained a closing bid price of $1.00 or greater for ten consecutive business days. This development is a positive milestone for Evaxion, known for its innovative AI-Immunology platform aimed at developing advanced vaccines and immunotherapies. The company is committed to addressing significant medical needs through its pipeline of treatments for cancer and infectious diseases.
Read more →EVAX▲ +5.9%on this newsshared move
Evaxion Announces Closing of $15 Million Public Offering
Evaxion Biotech A/S has successfully closed a $15 million public offering of its American Depositary Shares (ADSs) on February 5, 2024. The offering, which includes warrants for additional ADSs, was supported by MSD Global Health Innovation Fund. The funds raised are earmarked for advancing Evaxion's clinical pipeline and managing ongoing operational expenses. This development highlights Evaxion's commitment to utilizing its AI-Immunology platform to develop immunotherapies for various diseases.
Read more →EVAX▲ +17%on this newsshared move
Evaxion Biotech Announces Pricing of $15 Million Public Offering
Evaxion Biotech A/S has announced a public offering of 3,750,000 American Depositary Shares (ADSs) priced at $4.00 each, aiming to raise $15 million. The proceeds will be utilized to advance the company’s clinical pipeline and support ongoing operations. Merck's MSD Global Health Innovation Fund is participating in this offering, reflecting confidence in Evaxion’s AI-Immunology platform. The offering is expected to close around February 5, 2024, pending customary conditions.
Read more →EVAX▲ +113.4%on this news
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
Evaxion Biotech A/S has announced an expansion in the development of tailored cancer vaccines utilizing a novel category of AI-identified tumor antigens known as Endogenous Retroviruses (ERVs). This innovative approach aims to address the treatment needs of patients who are unresponsive to conventional immunotherapies. The company plans to initiate preclinical activities to generate Proof-of-Concept data by the second half of 2024, marking a significant step forward in cancer vaccine applicability. Evaxion is leveraging its AI-Immunology platform to identify these promising ERV targets, which could revolutionize treatment protocols in oncology.
Read more →EVAX▼ -45.4%on this newsshared move
Evaxion Announces Completion of ADS Ratio Change
Evaxion Biotech A/S has announced the completion of its American Depositary Shares (ADS) ratio change, effective January 22, 2024. The ratio has shifted from one ADS representing one ordinary share to one ADS representing ten ordinary shares. This change, resembling a one-for-ten reverse stock split, aims to enhance ADS liquidity and help the company meet Nasdaq’s minimum bid price requirement. While the change does not affect shareholders' percentage ownership, it remains uncertain whether the trading price will reflect this adjustment positively.
Read more →EVAXDecember 2023 NOTICE OF EXTRAORDINARY GENERAL MEETING EVAXION BIOTECH A/S 11 JANUARY 2024 AT 15:00 (CET) The board of directors hereby convenes an extraordinary general meeting of Evaxion Biotech A/S, company registratio
Evaxion Biotech A/S has scheduled an extraordinary general meeting for January 11, 2024, at 15:00 CET. The board of directors will propose several amendments to the company's articles of association, including authorizations for issuing warrants and increasing share capital amounts. Specific changes include raising the authorization in articles regarding warrants for board members, employees, and external parties, as well as increasing the nominal share capital from DKK 6,568 to DKK 1,000,000. The meeting aims to implement these adjustments to facilitate capital raises and enhance shareholder engagement.
Read more →EVAXEvaxion Announces Plan to Implement ADS Ratio Change
Evaxion Biotech A/S announced a change to the ratio of its American Depositary Shares (ADSs), moving from one ADS representing one ordinary share to one ADS representing ten ordinary shares. This change, effective around January 22, 2024, aims to improve liquidity and comply with Nasdaq's minimum bid price requirement. However, the company has indicated there is no guarantee that this will result in a proportional increase in ADS trading price or improved liquidity. The firm continues to innovate in developing AI-powered vaccines.
Read more →EVAXEvaxion Biotech Announces Closing of Private Placement MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offeri
Evaxion Biotech A/S has successfully closed a private placement, securing gross proceeds of approximately $5.3 million. Notably, MSD Global Health Innovation Fund became the largest new shareholder, contributing around 25% of the total offering. The funds raised will be utilized for working capital and general corporate purposes, enhancing Evaxion’s financial stability as it develops AI-driven vaccines. The company also plans to register the securities issued in this private placement with the SEC in the future.
Read more →EVAXEvaxion Announces Business Update and Third Quarter 2023 Financial Results Christian Kanstrup joined Evaxion as Chief Executive Officer in September Evaxion has launched its refined strategy with an increased focus on va
Evaxion Biotech A/S has provided a business update and reported its third quarter 2023 financial results, revealing cash and cash equivalents of $2.6 million. The company has priced a bridge financing round expected to raise approximately $5.3 million, aimed at funding operations into early 2024. Under new CEO Christian Kanstrup, Evaxion is focusing on its AI-Immunology platform, highlighting recent successful partnerships and encouraging Phase 2 data for its personalized cancer vaccine candidate EVX-01, although the company anticipates a significant cash burn in the upcoming year.
Read more →EVAXEvaxion Biotech Announces Private Placement Financing MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offerin
Evaxion Biotech A/S has announced a successful private placement financing generating approximately $5.3 million. The offering includes notable participation from MSD Global Health Innovation Fund, which accounts for about 25% of the total financing. The funds will be used for working capital and corporate purposes, highlighting confidence from current and new shareholders in the company's strategic direction. The transaction is expected to close around December 21, 2023, subject to customary closing conditions.
Read more →EVAXEvaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency October 5,, 2023
Evaxion Biotech A/S has received a notification from Nasdaq regarding a deficiency in the bid price of its American Depositary Shares (ADSs), which has been under the $1.00 minimum requirement for thirty business days. The company has 180 days to regain compliance, with options including implementing a reverse share split. The notification does not immediately impact the trading of its ADSs, and the company intends to resolve the deficiency within the given timeframe. If necessary, an additional compliance period could be available if the initial deadline is not met.
Read more →EVAX▼ -20.5%on this news· ran to -36% by day 1
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
Evaxion Biotech A/S has announced the initiation of a preclinical program for EVX-B3, an AI-designed vaccine targeting an undisclosed bacterial pathogen in collaboration with a leading pharmaceutical company. The project will utilize Evaxion's proprietary AI platforms, EDEN and RAVEN, to identify protective antigens capable of eliciting robust immune responses. This collaboration seeks to address a significant global health challenge associated with recurrent infections for which no vaccines exist. The venture underscores the potential of AI in developing innovative immunotherapies.
Read more →EVAX▼ -8%on this news
Evaxion Announces Business Update and Second Quarter 2023 Financial Results Promising clinical data from Phase 1 and 2a studies with EVX-01 and EVX-02 were presented at AACR and ASCO in Q2 2023 A novel proprietary geneti
Evaxion Biotech A/S announced a business update and second quarter 2023 financial results, highlighting promising early clinical data for its cancer immunotherapies, EVX-01 and EVX-02. The company has successfully secured up to $20 million in financing to support ongoing research initiatives. Notably, preclinical data for EVX-B1 indicates its capacity to effectively clear Staphylococcus infections. However, the company emphasized the need for an additional $5-10 million in funding to advance its clinical trials.
Read more →EVAXEVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ​ Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three and Six Months Ended
Evaxion Biotech A/S disclosed its unaudited condensed consolidated interim financial statements for the second quarter ending June 30, 2023. The company incurred a net loss of $5,683,000, with total operating expenses reported at $5,677,000. The significant drop in cash and cash equivalents, which decreased from $13,184,000 to $7,118,000, raises liquidity concerns. These financial results highlight ongoing challenges as the company continues its research and development efforts in AI-powered immunotherapies.
Read more →EVAXEvaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccine
Evaxion Biotech has introduced a proprietary genetic adjuvant technology designed to enhance the efficacy of DNA and mRNA vaccines, particularly against infectious diseases and cancer. The adjuvant, which encodes the immune-stimulating molecule CCL19, has demonstrated significant preclinical success, inducing strong T-cell responses and high antibody levels. The company plans to evaluate this technology in clinical trials as part of its personalized cancer immunotherapy program, EVX-03, later in 2023. This development underscores Evaxion's commitment to advancing vaccine technology and improving treatment options in immunotherapy.
Read more →EVAXEvaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01 Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor
Evaxion Biotech has announced positive results from its Phase 1 clinical trial for the personalized cancer vaccine EVX-01, demonstrating an objective response in 67% of patients when combined with a checkpoint inhibitor. The trial met its primary endpoints for tolerability and safety, with manageable adverse effects. The findings highlight the efficacy of Evaxion's AI platform in selecting immunogenic neoantigens for personalized vaccines. Interim results from the ongoing Phase 2 study are expected in the fourth quarter of 2023.
Read more →EVAXMay 2023 NOTICE OF ANNUAL GENERAL MEETING EVAXION BIOTECH A/S 24 MAY 2023 AT 14:00 (CEST) The board of directors hereby convenes the Annual General Meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76 28
Evaxion Biotech A/S has announced its Annual General Meeting scheduled for May 24, 2023, at its headquarters. The meeting will include discussions on company activities from the previous year and the proposed re-election of several board members. The audited report for 2022 is also recommended for approval. Shareholders must confirm their attendance in advance and can vote in person or by proxy.
Read more →EVAX▼ -10.9%on this news
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints - All 10 patients with late stage melanoma who completed EVX-02
Evaxion Biotech A/S announced promising results from its Phase 1/2a trial for the DNA-based cancer immunotherapy EVX-02, showing that all 10 patients with late-stage melanoma remained relapse-free. The study successfully met its primary endpoints regarding safety and immunogenicity, as well as a secondary endpoint on clinical efficacy. Evaxion's AI platform was validated through these results, which support the company's plan to accelerate the development of the next-generation therapy, EVX-03. The findings were presented at the 2023 AACR meeting, highlighting the potential of EVX-02 in personalized cancer treatment.
Read more →EVAXEvaxion Biotech A S VIF Proof 1 Extraordinary General Meeting of the Shareholders of Evaxion Biotech A/S Date
Evaxion Biotech A/S has convened an Extraordinary General Meeting scheduled for February 21, 2023. The meeting will cover several key proposals, including the election of a chairman and authorizations for the Board of Directors to issue investor warrants and increase share capital. Registered owners of American Depositary Receipts are instructed to vote on these proposals prior to the meeting date. Instructions for voting have been outlined, and all votes must be received by February 16, 2023.
Read more →EVAXJanuary 2023 NOTICE OF EXTRAORDINARY GENERAL MEETING EVAXION BIOTECH A/S 21 FEBRUARY 2023 AT 17:00 (CET) The Board of Directors hereby convenes an Extraordinary General Meeting of Evaxion Biotech A/S, company registratio
Evaxion Biotech A/S has convened an Extraordinary General Meeting scheduled for 21 February 2023, at which multiple proposals will be discussed. Key agenda items include the election of a chairman and authorizing the Board to issue up to 30 million warrants for investors and consultants. The meeting will also address amendments to the articles of association regarding share issuance. Shareholders are required to notify their attendance and may vote by proxy or in person.
Read more →EVAX▲ +22.6%on this news
Important Milestone Reached for Evaxion Biotech's EVX-01 Personalized Cancer Therapy COPENHAGEN, Denmark, Sep. 21 st , 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-
Important Milestone Reached for Evaxion Biotech's EVX-01 Personalized COPENHAGEN, Denmark, Sep. 21st, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven i
Read more →EVAXEvaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLC Announced successful production of personalized ca
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update Copenhagen, Denmark, August 10, 2022 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the dev
Read more →EVAXEvaxion Biotech A/S Announces Executive Management Changes
Evaxion Biotech A/S Announces Executive Management Changes Denmark, August 2, 2022 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today anno
Read more →EVAXxA9; Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2022. Anticipated Key Milestones 2022-23 2 AI Platform Indication Product Candidate Phase 2022 2023 2024 PIONEER Immuno-oncology Metastatic Me
Aureus EVX-B1 Pre-clinical H2 Regulatory filing Phase 1/2 EDEN Infectious diseases N. Gonorrhoeae EVX-B2 Pre-clinical H1 Selection of second bacterial target Partnership RAVEN Infectious diseases EVX-V1 Pre-clinical H2 Selection of first viral product candidate Partnership
Read more →EVAXEvaxion Biotech Announces Gonorrhea as Second Bacterial Product Target Copenhagen, Denmark
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Denmark, June 30, 2022 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that th
Read more →EVAX▲ +5.1%on this news
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer Copenhagen, Denmark
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Denmark, June 23, 2022 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced t
Read more →EVAX▲ +10.2%on this news
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital Copenhagen, Denmark
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital Denmark, June 7, 2022 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies
Read more →EVAX▼ -9.4%on this news
EVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ​ Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three Months Ended
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three Months Ended March 31, 2022 and 2021 2 Unaudited Condensed Consolidated Interim Statements of Financial Position a
Read more →EVAX▼ -15.1%on this newsshared move
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanoma Completed
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update Copenhagen, Denmark, May 11, 2022 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the develop
Read more →EVAX▼ -5.9%on this newsshared move
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02. Copenhagen, Denmark
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02. Denmark, May 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development
Read more →EVAXApril 2022 NOTICE OF ANNUAL GENERAL MEETING EVAXION BIOTECH A/S 3 MAY 2022 AT 4.00 PM (CEST) The board of directors hereby convenes the Annual General Meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76
NOTICE OF ANNUAL GENERAL MEETING 3 MAY 2022 AT 4.00 PM (CEST) The board of directors hereby convenes the Annual General Meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76 28 63 (the "Company"), to be held on 3 May 2022 at 4.00 PM (CEST) at c/o Evaxion Biote
Read more →EVAXEvaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Completed follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Denmark, March 22, 2022 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the dev
Read more →EVAXEvaxion Biotech Strengthens Management Team with Two Senior Appointments Copenhagen, Denmark
Evaxion Biotech Strengthens Management Team with Two Senior Appointments Copenhagen, Denmark, March 14, 2022 (GLOBE NEWSWIRE)- Evaxion Biotech A/S (NASDAQ: EVAX) is a clinical-stage biotechnological company specializing in the development of AI-powered immunotherapies to impro
Read more →EVAXEvaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02 Copenhagen, Denmark
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial Copenhagen, Denmark, March 7, 2022 - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now finalized recruitment for P
Read more →EVAXEvaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA for Treatment of Melanoma Copenhagen, Denmark
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA for Treatment of Melanoma Denmark, Jan. 18, 2022 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the dev
Read more →EVAXEVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ​ Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three and Nine Months Ended
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2021 and 2020 2 Unaudited Condensed Consolidated Interim Statements of Financi
Read more →EVAXEvaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares Copenhagen, Denmark
Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares Copenhagen, Denmark, November 9, 2021 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-s
Read more →EVAXEvaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depository Shares (ADSs) for gross
Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update Copenhagen, Denmark, November 9, 2021 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunothe
Read more →EVAXEvaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering Copenhagen, Denmark
Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering Copenhagen, Denmark, November 5, 2021 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunother
Read more →EVAXEvaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital Copenhagen, Denmark
Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital Copenhagen, Denmark, October 26, 2021 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (Nasdaq: EVAX) ("Evaxion" or the "Company"), a clinical-stage b
Read more →EVAXEvaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA (pembrolizumab) in Patients with Melanoma Copenhagen, Denmark
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA (pembrolizumab) in Patients with Melanoma Denmark, October 25, 2021(GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in th
Read more →EVAXEvaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update Data reported in early July from EVX-01 clinical program showed a robust anti-tumor effect in combination with anti-PD-1 treatment for pati
Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update Copenhagen, Denmark, August 12, 2021 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunother
Read more →EVAXEvaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02 New clinical data demonstrates antitumor effect of EVX-01 in combination with anti-PD1 treatment Objective Response Rate (ORR) of 67% with EVX-01 +
Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and Copenhagen, Denmark, July 8, 2021 - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotech company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer
Read more →EVAXEvaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic Programming Copenhagen, Denmark
Evaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic Programming Copenhagen, Denmark, June 25, 2021 - Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve th
Read more →EVAXJune 2021 Notice of extraordinary general meeting Evaxion biotech a/S 7 July 2021 at 18.00 (CEST) The board of directors hereby convenes an Extraordinary General Meeting of Evaxion Biotech A/S, company registration (CVR)
of extraordinary general meeting The board of directors hereby convenes an Extraordinary General Meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76 28 63 (the "Company"), to be held on 7 July 2021 at 18.00 (CEST) at c/o Evaxion Biotech A/S, Dr Neergaards Vej
Read more →EVAXEvaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion's AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine Copenhagen, Denmark
Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion's AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine Denmark, June 03, 2021 - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotech company developing AI-driven im
Read more →EVAXEvaxion Biotech Appoints Lars Holtug to the Board of Directors Copenhagen, Denmark
Evaxion Biotech Appoints Lars Holtug to the Board of Directors Denmark, May 26, 2021 - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infect
Read more →EVAXEVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three Months Ended
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three Months Ended March 31, 2021 and 2020 2 Unaudited Condensed Consolidated Interim Statements of Financial Position a
Read more →EVAXEvaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update Raised net proceeds of $27.9 million in U.S. initial public offering in February 2021 Lead programs EVX-01 and EVX-02 on track for Phase 1/
Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update Copenhagen, Denmark, May 13, 2021 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapi
Read more →EVAXApril 2021 Notice of annual general meeting Evaxion biotech a/S Tuesday 25 May 2021 at 15:00 (CEST) The board of directors hereby convenes the Annual General Meeting of Evaxion Biotech A/S, company registration (CVR) no.
of annual general meeting 25 May 2021 at 15:00 (CEST) The board of directors hereby convenes the Annual General Meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76 28 63 (the "Company"), to be held on Tuesday 25 May 2021 at 15:00 (CEST) at c/o Evaxion Biotec
Read more →EVAXEvaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million Clinica
Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update Denmark, April 6, 2021 (GLOBAL NEWSWIRE) - Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to
Read more →Competitive Position
How EVAX ranks across every disease it competes inCompetitive Position is a premium feature
See how EVAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial